help button home button Am J Pathol Epitomics, Inc.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Originally published online as doi:10.2353/ajpath.2009.090059 on October 1, 2009

Published online before print October 1, 2009
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ajpath.2009.090059v1
175/5/2076    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Mastrangelo, M. A.
Right arrow Articles by Bowers, W. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mastrangelo, M. A.
Right arrow Articles by Bowers, W. J.
(American Journal of Pathology. 2009;175:2076-2088.)
© 2009 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2009.090059

Interferon-{gamma} Differentially Affects Alzheimer’s Disease Pathologies and Induces Neurogenesis in Triple Transgenic-AD Mice

Michael A. Mastrangelo*, Kelly L. Sudol*, Wade C. Narrow* and William J. Bowers*{dagger}{ddagger}

From the Center for Neural Development and Disease* and the Departments of Neurology{dagger} and Microbiology and Immunology,{ddagger} University of Rochester Medical Center, Rochester, New York

Inflammatory processes, including the episodic and/ or chronic elaboration of cytokines, have been identified as playing key roles in a number of neurological disorders. Whether these activities impart a disease-resolving and/or contributory outcome depends at least in part on the disease context, stage of pathogenesis, and cellular milieu in which these factors are released. Interferon-{gamma} (IFN{gamma}) is one such cytokine that produces pleiotropic effects in the brain. It is protective by ensuring maintenance of virus latency after infection, yet deleterious by recruiting and activating microglia that secrete potentially damaging factors at sites of brain injury. Using the triple-transgenic mouse model of Alzheimer’s disease (3xTg-AD), which develops amyloid and tau pathologies in a pattern reminiscent of human Alzheimer’s disease, we initiated chronic intrahippocampal expression of IFN{gamma} through delivery of a serotype-1 recombinant adeno-associated virus vector (rAAV1-IFN{gamma}). Ten months of IFN{gamma} expression led to an increase in microglial activation, steady-state levels of proinflammatory cytokine and chemokine transcripts, and severity of amyloid-related pathology. In contrast, these rAAV1-IFN{gamma}-treated 3xTg-AD mice also exhibited diminished phospho-tau pathology and evidence of increased neurogenesis. Overall, IFN{gamma} mediates what seem to be diametrically opposed functions in the setting of AD-related neurodegeneration. Gaining an understanding as to how these apparently divergent functions are interrelated and controlled could elucidate new therapeutic strategies designed to harness the neuroprotective activity of IFN{gamma}.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Society for Investigative Pathology.